Annovis Bio Inc ((ANVS)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Study Overview: Annovis Bio Inc. is conducting a clinical trial titled ‘A 6-month & 18-month Prospective, Randomized, Placebo-controlled, Double-blind Dual Clinical Trial Investigating Efficacy and Safety of Buntanetap in Treating Participants of Early Alzheimer’s Disease.’ The study aims to evaluate the efficacy and safety of buntanetap/Posiphen in improving cognition and function in adults aged 55-85 with early Alzheimer’s disease, using measures like ADAS-Cog13 and ADCS-iADL.
Intervention/Treatment: The study tests the drug buntanetap/Posiphen, administered as a 30mg capsule taken orally once daily for 18 months. It is compared to a placebo to assess its effectiveness in treating early Alzheimer’s disease.
Study Design: The study is interventional and follows a randomized, parallel assignment model with quadruple masking, meaning participants, care providers, investigators, and outcomes assessors are blinded. The primary purpose is treatment-focused.
Study Timeline: The study began on February 4, 2025, with primary completion expected 18 months later. The latest update was submitted on July 14, 2025, indicating ongoing recruitment and progress.
Market Implications: This clinical trial update could positively influence Annovis Bio Inc.’s stock performance and investor sentiment, as successful outcomes may enhance the company’s market position in Alzheimer’s treatment. Competitors in the Alzheimer’s drug market will likely monitor these developments closely.
The study is ongoing, with further details available on the ClinicalTrials portal.